{"id":"sildenafil","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"","severity":"common","organSystem":""},{"effect":"Flushing","drugRate":"","severity":"common","organSystem":""},{"effect":"Pain in limb","drugRate":"","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"","severity":"common","organSystem":""},{"effect":"Back pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Edema","drugRate":"25%","severity":"common","organSystem":""}],"contraindications":["Acute coronary syndrome","Acute nephropathy","Anterior ischemic optic neuropathy","Aortic valve stenosis","Cerebrovascular accident","Chronic heart failure","Dehydration","Esophageal dysmotility","Fibrosis of corpus cavernosum","Hb SS disease","Hearing loss","Hepatic failure","Hereditary Degeneration of Retina","Hypertensive urgency","Idiopathic hypertrophic subaortic stenosis","Induratio penis plastica","Leukemia, disease","Life-Threatening Cardiac Arrhythmias","Low blood pressure","Multiple myeloma","Myocardial infarction","Penis bent","Pigmentary Retinopathy","Priapism","Pulmonary veno-occlusive disease","Severe Autonomic Insufficiency"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Myocardial infarction","drugRate":"","severity":"serious"},{"effect":"Sudden cardiac death","drugRate":"","severity":"serious"},{"effect":"Ventricular arrhythmia","drugRate":"","severity":"serious"},{"effect":"Cerebrovascular hemorrhage","drugRate":"","severity":"serious"},{"effect":"Transient ischemic attack","drugRate":"","severity":"serious"},{"effect":"Pulmonary hemorrhage","drugRate":"","severity":"serious"},{"effect":"Subarachnoid hemorrhage","drugRate":"","severity":"serious"},{"effect":"Intracerebral hemorrhage","drugRate":"","severity":"serious"},{"effect":"NAION (Nonarteritic anterior ischemic optic neuropathy)","drugRate":"","severity":"serious"},{"effect":"Seizure","drugRate":"","severity":"serious"}]},"status":"approved","trials":["NCT00302211","NCT00640458","NCT04914806","NCT01046838","NCT03462017","NCT00334490","NCT06123156","NCT00853112","NCT01091870","NCT04882826","NCT02908490","NCT07057011","NCT01572363","NCT05741229","NCT01347008","NCT01409993","NCT00730067","NCT06860399","NCT00527995","NCT00746967","NCT05782244","NCT01441934","NCT02129725","NCT00478335","NCT01169519","NCT00350441","NCT02304705","NCT00159848","NCT03945643","NCT00151463","NCT03475160","NCT05669885","NCT00143260","NCT00617305","NCT01449253","NCT00056433","NCT03610217","NCT00512707","NCT03633565","NCT00904748","NCT03364244","NCT04304313","NCT03696758","NCT01481350","NCT03142568","NCT02626182","NCT04114240","NCT00194597","NCT01889966","NCT02951429"],"aliases":["Viagra","Revatio"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.2187/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$80","description":"SILDENAFIL 100 MG TABLET","retrievedDate":"2026-04-07"}],"allNames":"viagra","offLabel":[],"timeline":[],"aiSummary":"Sildenafil (Viagra/Revatio) was the first PDE5 inhibitor, developed serendipitously by Pfizer and approved in 1998. One of the most recognizable drugs in history, it treats both erectile dysfunction and pulmonary arterial hypertension. Available generically since 2017.","brandName":"Viagra","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, Multidrug resistance-associated protein 5","novelty":"","modality":"Small molecule","drugClass":"PDE5 inhibitor","explanation":"Sildenafil was originally developed by Pfizer for angina, but clinical trials revealed its remarkable effect on erectile function as a side effect. It inhibits PDE5, the enzyme that breaks down cGMP in smooth muscle, prolonging the vasodilatory effect of nitric oxide signaling. As Viagra, it became a cultural phenomenon. As Revatio, it treats pulmonary arterial hypertension. Now available generically.","oneSentence":"Selectively inhibits phosphodiesterase type 5 (PDE5), increasing cGMP levels to relax smooth muscle in the corpus cavernosum and pulmonary vasculature.","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"},{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"sildenafil","indications":{"approved":[{"name":"Impotence","diseaseId":"impotence","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pulmonary arterial hypertension","diseaseId":"pulmonary-arterial-hypertension","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00302211","phase":"Phase 3","title":"A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of Inhaled Iloprost in Patients With Pulmonary Arterial Hypertension Receiving Oral Sildenafil","status":"TERMINATED","sponsor":"Actelion","isPivotal":true,"enrollment":67,"indication":"Pulmonary Hypertension","completionDate":"2008-07-01"},{"nctId":"NCT00640458","phase":"Phase 2","title":"A Double Blind, Placebo Controlled 2-way Cross-over Study to Assess the Clitoral Engorgement Response as Measured by Non-contrast Magnetic Resonance Imaging (MRI) in Women With Female Sexual Arousal D","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":20,"indication":"Female Sexual Arousal Disorder","completionDate":"2007-03"},{"nctId":"NCT04914806","phase":"N/A","title":"Association Between Premature Birth and Its Comorbidities With NO and the HPG Activation at Minipuberty","status":"UNKNOWN","sponsor":"National and Kapodistrian University of Athens","isPivotal":false,"enrollment":240,"indication":"Prematurity, Respiratory Distress Syndrome, Newborn","completionDate":"2025-12-31"},{"nctId":"NCT01046838","phase":"Phase 4","title":"SIDAMI - Sildenafil and Diastolic Dysfunction After AMI","status":"COMPLETED","sponsor":"Jacob E Mueller","isPivotal":false,"enrollment":70,"indication":"Heart Failure, Diastolic","completionDate":"2012-05"},{"nctId":"NCT03462017","phase":"Phase 1","title":"Study to Assess the Pharmacodynamic Effects of Repeated Oral Doses of SAR247799 on Endothelial Function in Male and Female Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","isPivotal":false,"enrollment":54,"indication":"Microvascular Coronary Artery Disease","completionDate":"2018-12-22"},{"nctId":"NCT00334490","phase":"Phase 2","title":"A Phase II, Double Blind Randomized Controlled Trial to Determine the Safety and Efficacy of 12.5mg of Oral Sildenafil (Viagra) Compared to Placebo to Decrease Pulmonary Hypertension in Cardiac Patien","status":"COMPLETED","sponsor":"Unity Health Toronto","isPivotal":false,"enrollment":40,"indication":"Pulmonary Hypertension","completionDate":"2009-05"},{"nctId":"NCT06123156","phase":"Phase 3","title":"Intérêt de la rééducation érectile précoce Par Sildénafil après radiothérapie et Proctectomie Pour Cancer du Rectum : Essai contrôlé randomisé","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","isPivotal":true,"enrollment":188,"indication":"Rectal Cancer","completionDate":"2030-02"},{"nctId":"NCT00853112","phase":"Phase 2","title":"A Phase 2a, Randomized, Double Blind, Placebo-controlled, Parallel Group Study Investigating The Dose-response Of Pf-00489791 On Acute Hemodynamics In Subjects With Idiopathic And Familial Pulmonary A","status":"TERMINATED","sponsor":"Pfizer","isPivotal":false,"enrollment":48,"indication":"Hypertension, Pulmonary","completionDate":"2010-07"},{"nctId":"NCT01091870","phase":"Phase 2","title":"Sildenafil for Prevention of Cerebral Vasospasm Secondary to Subarachnoid Haemorrhage - Phase II Randomized Clinical Trial","status":"WITHDRAWN","sponsor":"Hospital de Clinicas de Porto Alegre","isPivotal":false,"enrollment":0,"indication":"Subarachnoid Hemorrhage, Cerebral Vasospasm","completionDate":""},{"nctId":"NCT04882826","phase":"Phase 1","title":"Randomized Crossover 2 Period Single Dose Bioequivalence Study of 2 Formulations Sildenafil Tablets 100mg (Pharmtechnology LLC, Belarus) and Viagra® Tablets 100mg (Fareva Amboise, France) in Healthy M","status":"UNKNOWN","sponsor":"Pharmtechnology LLC","isPivotal":false,"enrollment":44,"indication":"Bioequivalence","completionDate":"2021-05-30"},{"nctId":"NCT02908490","phase":"Phase 2","title":"Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?","status":"TERMINATED","sponsor":"Kimberly Liang","isPivotal":false,"enrollment":25,"indication":"Arthritis, Rheumatoid, Atherosclerosis","completionDate":"2020-12-31"},{"nctId":"NCT07057011","phase":"NA","title":"Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy in Premature Ejaculation Patients With the Serotonin Transport","status":"NOT_YET_RECRUITING","sponsor":"South Valley University","isPivotal":false,"enrollment":60,"indication":"Premature Ejaculation","completionDate":"2026-02-10"},{"nctId":"NCT01572363","phase":"NA","title":"Fontan Patients: Comprehensive Evaluation of the Pulmonary Circulation to Identify Pulmonary Vascular Disease and Its Influence on Ventricular Hemodynamics.","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","isPivotal":false,"enrollment":10,"indication":"Congenital Heart Disease","completionDate":"2014-03"},{"nctId":"NCT05741229","phase":"NA","title":"The Effect Of Nebulizied Nitroglycerin As An Adjuvant Drug In Management Of Persistent Pulmonary Hypertension Of Newborns","status":"COMPLETED","sponsor":"Alexandria University","isPivotal":false,"enrollment":80,"indication":"Persistent Pulmonary Hypertension of the Newborn, Echocardiography","completionDate":"2025-01-20"},{"nctId":"NCT01347008","phase":"Phase 3","title":"Effect of Sildenafil on the Microcirculatory Blood Flow and on the Endothelial Progenitor Cells in Patients With Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial","status":"COMPLETED","sponsor":"Federal University of São Paulo","isPivotal":true,"enrollment":41,"indication":"Scleroderma, Systemic, Scleroderma, Diffuse","completionDate":"2013-01"},{"nctId":"NCT01409993","phase":"Phase 4","title":"","status":"TERMINATED","sponsor":"Vanderbilt University","isPivotal":false,"enrollment":78,"indication":"Impaired Glucose Tolerance","completionDate":"2016-11"},{"nctId":"NCT00730067","phase":"Phase 4","title":"Sildenafil for COPD-associated Pulmonary Hypertension. A Randomized Double Blinded Placebo Controlled Study.","status":"WITHDRAWN","sponsor":"University of Aarhus","isPivotal":false,"enrollment":0,"indication":"COPD, Pulmonary Hypertension","completionDate":"2012-12"},{"nctId":"NCT06860399","phase":"Phase 1","title":"The Effectiveness of Vardenafil Vs Sildenafil for The Treatment of Pulmonary Hypertension of the Newborn","status":"COMPLETED","sponsor":"Damascus University","isPivotal":false,"enrollment":55,"indication":"PPHN","completionDate":"2024-09-30"},{"nctId":"NCT00527995","phase":"Phase 3","title":"Acute Effects of Sildenafil on Flow Mediated Dilatation and Cardiovascular Autonomic Nerve Function in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Ruhr University of Bochum","isPivotal":true,"enrollment":40,"indication":"Type 2 Diabetes Mellitus, Endothelial Dysfunction","completionDate":"2003-06"},{"nctId":"NCT00746967","phase":"Phase 2","title":"An Open-Label, Multi-Center Extension Study To Evaluate The Safety, Toleration And Sustained Efficacy Of Oral Sildenafil Administered To Women Who Have Been Diagnosed With Female Sexual Arousal Disord","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":267,"indication":"Sexual Dysfunctions, Psychological, Sexual Arousal Disorder","completionDate":"2004-02"},{"nctId":"NCT05782244","phase":"Phase 2","title":"Phase 2 Randomized Controlled Trial of Sildenafil Citrate for Treatment of Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury","status":"RECRUITING","sponsor":"University of Pennsylvania","isPivotal":false,"enrollment":160,"indication":"Traumatic Brain Injury","completionDate":"2027-12-31"},{"nctId":"NCT01441934","phase":"Phase 3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of Sildenafil in the Treatment of Patients With Pulmonary Hypertension Associated to Chronic Obstructive Lung Di","status":"UNKNOWN","sponsor":"Italian Association of Hospital Pneumologists","isPivotal":true,"enrollment":32,"indication":"Pulmonary Hypertension, COPD","completionDate":"2013-02"},{"nctId":"NCT02129725","phase":"Phase 4","title":"Renin- Angiotensin and Fibrinolysis Interaction in Humans: Effect of Long-term PDE-5 Inhibition on Glucose Homeostasis. Sub-study","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","isPivotal":false,"enrollment":15,"indication":"Metabolic Syndrome","completionDate":"2016-12"},{"nctId":"NCT00478335","phase":"NA","title":"Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus","status":"COMPLETED","sponsor":"University of Colorado, Denver","isPivotal":false,"enrollment":4,"indication":"Nephrogenic Diabetes Insipidus","completionDate":"2012-10"},{"nctId":"NCT01169519","phase":"Phase 1","title":"Safety, Pharmacokinetics and Hemodynamic Efficacy of Sildenafil in Single Ventricle Patients","status":"COMPLETED","sponsor":"Duke University","isPivotal":false,"enrollment":21,"indication":"Heart Disease","completionDate":"2012-12"},{"nctId":"NCT00350441","phase":"Phase 4","title":"A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study of the Pre-Operative Effect of Sildenafil Citrate on Pulmonary Related Complications Following Cardiopulmonary Bypass in Children Un","status":"UNKNOWN","sponsor":"NHS Greater Glasgow Yorkhill Division","isPivotal":false,"enrollment":12,"indication":"Cardiopulmonary Bypass","completionDate":""},{"nctId":"NCT02304705","phase":"Phase 4","title":"Sildenafil in Heart Failure With Reactive Pulmonary Hypertension","status":"TERMINATED","sponsor":"Maya Guglin","isPivotal":false,"enrollment":33,"indication":"Heart Failure With Reactive Pulmonary Hypertension","completionDate":"2017-06"},{"nctId":"NCT00159848","phase":"Phase 4","title":"Effectiveness Of An Educational Program To Improve Patients' Satisfaction Regarding Their Management Of Erectile Dysfunction With Sildenafil","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":8000,"indication":"Impotence","completionDate":"2003-09"},{"nctId":"NCT03945643","phase":"EARLY/Phase 1","title":"Is Blood Flow Through IPAVA and PFO Related to Breath-hold and SCUBA Diving-induced Pulmonary Hypertension?","status":"COMPLETED","sponsor":"University of Oregon","isPivotal":false,"enrollment":82,"indication":"Patent Foramen Ovale, Intrapulmonary Arteriovenous Anastamosis","completionDate":"2023-07-31"},{"nctId":"NCT00151463","phase":"Phase 4","title":"An Open-Label, Non-Comparative Study To Evaluate Treatment Responsiveness To The Quality Of Erection Questionnaire (QEQ) In Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":100,"indication":"Impotence","completionDate":""},{"nctId":"NCT03475160","phase":"NA","title":"Sildenafil Citrate for Treatment of Unexplained Recurrent Spontaneous Abortion","status":"COMPLETED","sponsor":"Benha University","isPivotal":false,"enrollment":130,"indication":"Recurrent Abortion","completionDate":"2017-12-01"},{"nctId":"NCT05669885","phase":"NA","title":"Hypersensitivity to Phosphodiesterase 5 Inhibition in Post-Traumatic Headache: A Randomized Clinical Trial","status":"UNKNOWN","sponsor":"Danish Headache Center","isPivotal":false,"enrollment":21,"indication":"Post-Traumatic Headache","completionDate":"2023-12-31"},{"nctId":"NCT00143260","phase":"Phase 4","title":"Multicenter Randomized Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose - II","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":250,"indication":"Impotence","completionDate":"2006-05"},{"nctId":"NCT00617305","phase":"Phase 4","title":"An Open-label, Multicenter Study of Ambrisentan and a Phosphodiesterase Type-5 Inhibitor Combination Therapy in Subjects With Pulmonary Arterial Hypertension Who Have Demonstrated a Sub-Optimal Respon","status":"COMPLETED","sponsor":"Gilead Sciences","isPivotal":false,"enrollment":38,"indication":"Pulmonary Arterial Hypertension","completionDate":"2011-07"},{"nctId":"NCT01449253","phase":"Phase 4","title":"Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences","isPivotal":false,"enrollment":60,"indication":"Pulmonary Hypertension Secondary to Lung Disease and/or Hypoxia","completionDate":"2013-07"},{"nctId":"NCT00056433","phase":"Phase 1","title":"Evaluation of Potential Synergy of Combining Hydroxyurea With Nitric Oxide Donors on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","isPivotal":false,"enrollment":39,"indication":"Sickle Cell Anemia","completionDate":"2006-12-27"},{"nctId":"NCT03610217","phase":"NA","title":"Pragmatic Clinical Trials in Scleroderma","status":"UNKNOWN","sponsor":"University of West London","isPivotal":false,"enrollment":400,"indication":"Scleroderma, Systemic, Sclerosis, Systemic","completionDate":"2021-10"},{"nctId":"NCT00512707","phase":"Phase 4","title":"Androgen Modulation of Response to Selective Phosphodiesterase Inhibitors in Erectile Dysfunction","status":"COMPLETED","sponsor":"Boston University","isPivotal":false,"enrollment":140,"indication":"Erectile Dysfunction, Testosterone Deficiency","completionDate":"2010-05"},{"nctId":"NCT03633565","phase":"Phase 4","title":"A Comparative Study of Strategies for Management of Duchenne Myopathy in Assiut University Children Hospital","status":"UNKNOWN","sponsor":"Assiut University","isPivotal":false,"enrollment":45,"indication":"Myopathy","completionDate":"2021-11"},{"nctId":"NCT00904748","phase":"Phase 1","title":"A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate In Healthy Male Subjects, Fasting Dosing, Being The Test Formulation Sildenafil Citrate 100 Mg CT , And The Reference Fo","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":47,"indication":"Erectile Dysfunction","completionDate":"2010-03"},{"nctId":"NCT03364244","phase":"N/A","title":"Revatio Special Investigation - Investigation for Long-Term Use of Revatio in Pediatric Patients","status":"COMPLETED","sponsor":"Viatris Pharmaceuticals Japan Inc","isPivotal":false,"enrollment":1023,"indication":"Pulmonary Arterial Hypertension","completionDate":"2022-08-30"},{"nctId":"NCT04304313","phase":"Phase 3","title":"A Pilot Study of Sildenafi in the Treatment of COVID-19","status":"UNKNOWN","sponsor":"Tongji Hospital","isPivotal":true,"enrollment":10,"indication":"COVID-19","completionDate":"2020-11-09"},{"nctId":"NCT03696758","phase":"Phase 2","title":"Improving Right Ventricular Function in Young Adults Born Preterm: A Pilot Study","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","isPivotal":false,"enrollment":10,"indication":"Infant,Premature","completionDate":"2020-02-24"},{"nctId":"NCT01481350","phase":"Phase 2","title":"Phase 2 Use of Sildenafil for the Treatment of Post-capillary Hypertension in Patients Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"University of Turin, Italy","isPivotal":false,"enrollment":20,"indication":"Pulmonary Hypertension","completionDate":"2013-12"},{"nctId":"NCT03142568","phase":"Phase 2","title":"Safety of Sildenafil in Premature Infants at Risk of Bronchopulmonary Dysplasia","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","isPivotal":false,"enrollment":109,"indication":"Bronchopulmonary Dysplasia","completionDate":"2025-03-01"},{"nctId":"NCT02626182","phase":"Phase 1","title":"Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe Cystic Fibrosis Lung Disease","status":"COMPLETED","sponsor":"National Jewish Health","isPivotal":false,"enrollment":14,"indication":"Cystic Fibrosis","completionDate":"2018-01-29"},{"nctId":"NCT04114240","phase":"N/A","title":"French Study in Real Life Evaluating Xybilun: Convenience and Erection Induction Related to a New Administration in Orodispersible Film","status":"COMPLETED","sponsor":"Laboratoires Genévrier","isPivotal":false,"enrollment":105,"indication":"Erectile Dysfunction","completionDate":"2019-04-26"},{"nctId":"NCT00194597","phase":"Phase 4","title":"Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III","status":"TERMINATED","sponsor":"University of Washington","isPivotal":false,"enrollment":30,"indication":"Prostatitis","completionDate":"2007-07"},{"nctId":"NCT01889966","phase":"Phase 4","title":"Vasoreactivity Testing With Intravenous Sildenafil in Patients With Precapillary Pulmonary Hypertension (Treatment Optimisation Study)","status":"COMPLETED","sponsor":"Kerckhoff Heart Center","isPivotal":false,"enrollment":10,"indication":"Pulmonary Hypertension Associated With Connective Tissue Disease","completionDate":"2015-01"},{"nctId":"NCT02951429","phase":"Phase 2","title":"A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients With Advanced Idiopathic ","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":false,"enrollment":177,"indication":"Idiopathic Pulmonary Fibrosis","completionDate":"2020-08-22"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Oral, Intravenous","frequency":"As needed (ED) or three times daily (PAH)","formulation":"Tablet, Oral suspension, IV injection"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"firstApprovalDate":"1998-03-27","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":"EMEA/H/C/004186"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Mysildecard","application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":15,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}